Holm L E, Dahlqvist I, Israelsson A, Lundell G
N Engl J Med. 1980 Jul 24;303(4):188-91. doi: 10.1056/NEJM198007243030404.
We studied the incidence of malignant thyroid tumors after 131I therapy in 2727 patients with hyperthyroidism and in 273 euthyroid patients with cardiac disease. The patients were all adults, with a mean age of 57 years. The 131I therapy was given between 1951 and 1965. The mean follow-up period was 13 years for the hyperthyroid patients (15 years for the 85 per cent surviving for more than five years) and six years for the cardiac patients (12 years for the 41 per cent surviving for more than five years). The incidence of malignant thyroid tumors was based on a search of the Swedish Cancer Registry for the occurrence of such tumors in any of the 3000 patients. At present there is no increased incidence of malignant thyroid tumors after 131I therapy (four cases observed versus 3.2 cases expected).
我们研究了2727例甲亢患者和273例甲状腺功能正常的心脏病患者接受¹³¹I治疗后甲状腺恶性肿瘤的发生率。所有患者均为成年人，平均年龄57岁。¹³¹I治疗于1951年至1965年期间进行。甲亢患者的平均随访期为13年（85%存活超过5年的患者为15年），心脏病患者的平均随访期为6年（41%存活超过5年的患者为12年）。甲状腺恶性肿瘤的发生率是基于对瑞典癌症登记处中这3000例患者中此类肿瘤发生情况的检索。目前，¹³¹I治疗后甲状腺恶性肿瘤的发生率没有增加（观察到4例，预期为3.2例）。
